The research team at CNS Healthcare, Orlando, Florida has been chosen to begin clinical trials on a medication for the prevention of COVID-19 and a vaccine to protect against contracting the virus.
Pharmaceutical companies, both large and small, are in a race to find treatment to prevent and end the spread of COVID-19 and to get it to market quickly.
Michael Dever, MD, Principal Investigator for CNS Healthcare stated, “We’ve previously partnered with these pharmaceutical companies to assist with treatments for influenza, the common cold, as well as vaccines for other viral and bacterial infections. We were chosen to conduct these important clinical trials because of our excellent reputation in the field of research and our exemplary track record. They know they can depend on us to provide the necessary data and we’ll accomplish it quickly.”
The data collected during these fast-track research studies will help the US Food and Drug Administration (FDA) to make decisions as to whether the therapies being tested are safe and effective for the FDA to give their stamp of approval.
The prophylaxis study will be seeking front-line healthcare workers and first responders who have been recently exposed to COVID-19.
The vaccine trial will be offered to healthy adults who have not been exposed to COVID-19.
CNS Healthcare is urging the community to help make a difference and join us to stop the spread of COVID-19. Learn more by contacting CNS Healthcare at 407-425-5100 or go to www.cnshealthcare.com.
Since 1996, CNS Healthcare has partnered to conduct world-class research that is providing for new and improved treatments which have resulted in the FDA approval of over 80 medications. With offices in Orlando, FL, Jacksonville, FL and Memphis, TN, they research diseases that affect both the physical and mental well-being of men, women and children, both now, and for generations to come.
